<DOC>
	<DOCNO>NCT02892318</DOCNO>
	<brief_summary>This non-randomized , open-label , Phase Ib study atezolizumab combination immunomodulatory agent treatment participant AML ( relapsed-refractory treatment-naive , elderly participant unfit induction chemotherapy ) . The study design intent , time , study multiple combination atezolizumab different immunomodulatory agent AML participant ( e.g. , umbrella study design ) . The study begin evaluation combination atezolizumab guadecitabine ( Arm A ) . In future , additional arm may add .</brief_summary>
	<brief_title>A Study Evaluating Safety Pharmacology Atezolizumab Administered Combination With Immunomodulatory Agents Participants With Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunologic Factors</mesh_term>
	<criteria>Life expectancy least 12 week Diagnosis AML per World Health Organization criterion Eastern Cooperative Oncology Group ( ECOG ) performance status score equal ( = ) 0 , 1 2 Specifically , participant Cohorts A1 A2 : Age great equal ( &gt; = ) 18 year , disease progression failure achieve complete partial response intensive cytotoxic therapy , participant receive two prior intensive regimen ( e.g. , induction + consolidation one salvage therapy + consolidation ) Specifically , participant Cohorts A3 A4 : Treatment na√Øve participant unfit induction chemotherapy AML define follow : Age &gt; = 70 Age 65 69 year least one following : ECOG performance status = 2 , Intermediate I/II adverse risk cytogenetic molecular alteration per European LeukemiaNet ( ELN ) 2010 guideline secondary AML , unfit receive induction cytotoxic chemotherapy Adequate endorgan function Willing able undergo pretreatment bone marrow aspirate biopsy subsequent ontreatment bone marrow aspirate biopsy For woman childbearing potential : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive method result failure rate le ( &lt; ) 1 percent ( % ) per year treatment period least 30 day last dose guadecitabine 90 day last dose atezolizumab , whichever long For men : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive measure , agreement refrain donate sperm In Cohorts A3 A4 , participant AML eligible standard intensive induction therapy anthracycline cytarabine Prior allogeneic stem cell transplant solid organ transplant Active central nervous system involvement leukemia Pregnant lactating , intend become pregnant study History idiopathic pulmonary fibrosis , organize pneumonitis , druginduced pneumonitis , idiopathic pneumonitis , autoimmune disease Treatment investigational therapy within 14 day prior initiation study drug Any approve AML related therapy within 14 day prior enrollment Immunosuppressive therapy within 6 week Cycle 1 , Day 1 Daily requirement corticosteroid ( &gt; 10 mg prednisone daily equivalent ) ( except inhalation corticosteroid ) within 2 week prior Cycle 1 , Day 1 Prior treatment immune checkpoint blockade therapy ( anticytotoxic Tlymphocyteassociated protein 4 [ antiCTLA4 ] , antiprogrammed death1 [ antiPD1 ] antiprogrammed deathligand 1 [ antiPDL1 ] ) immune agonist ( anticluster differentiation [ CD ] 137 , antiCD40 , antiOX40 ) Treatment systemic immunostimulatory agent within 6 week 5 halflives drug , whichever short , prior Cycle 1 , Day 1 Treatment denosumab ( receptor activator nuclear factor kappaB ligand [ RANKL ] inhibitor ) 4 week first dose 10 week last dose atezolizumab Administration live , attenuate vaccine within 4 week Cycle 1 , Day 1 anticipation live attenuated vaccine require study Planned major surgery study Positive hepatitis C virus ( HCV ) antibody screen Active hepatitis B virus ( HBV ) infection Positive human immunodeficiency virus ( HIV ) Illicit drug alcohol abuse within 12 month prior screen Poor peripheral venous access Active infection Serious infection require hospitalization intravenous ( IV ) antibiotic within 14 day prior enrollment Any serious medical condition abnormality clinical laboratory test History presence abnormal electrocardiogram ( ECG ) History malignancy within 2 year prior screen Known hypersensitivity biopharmaceuticals produce Chinese hamster ovary cell component atezolizumab guadecitabine formulation History severe allergic , anaphylactic hypersensitivity reaction chimeric humanize antibody fusion protein</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>